You are here

Europe

Here's Why Pacific Biosciences Is Tumbling Today

Here's Why Pacific Biosciences Is Tumbling Today

Motley Fool

Pacific Biosciences

Flag link:

Alexion’s Soliris follow-up Ultomiris snares EU approval

Alexion’s Soliris follow-up Ultomiris snares EU approval

Pharmaforum

Flag link:

Roche closes on EU approval for Tecentriq in breast cancer

Roche closes on EU approval for Tecentriq in breast cancer

Pharmaforum

triple negative breast cancer

Flag link:

Amgen/UCB hit another Evenity hurdle, as European regulators fail to back the osteoporosis drug

Amgen/UCB hit another Evenity hurdle, as European regulators fail to back the osteoporosis drug

Endpoints

Flag link:

'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops

'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops

Endpoints

Bristol-Myers Squibb

Flag link:

AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

Yahoo/Reuters

Flag link:

Bluebird sets $1.8M price tag for blood-disease gene therapy

Bluebird sets $1.8M price tag for blood-disease gene therapy

Biopharma Dive

beta thalassemia

Flag link:

5 Things You'll Want to Watch With GW Pharmaceuticals

5 Things You'll Want to Watch With GW Pharmaceuticals

Motley Fool

Flag link:

Germany's Stada buys six of GSK's consumer brands, eyes further deals

Germany's Stada buys six of GSK's consumer brands, eyes further deals

Yahoo/Reuters

consumer health

Flag link:

Bluebird Bio’s Gene Therapy for Blood Disease Wins European Approval

Bluebird Bio’s Gene Therapy for Blood Disease Wins European Approval

Xconomy

beta thalassemia

Flag link:

EMA imposes formal limit on Xeljanz prescription as regulators continue to review safety concerns

EMA imposes formal limit on Xeljanz prescription as regulators continue to review safety concerns

Endpoints

post-marketing studies

Flag link:

EU universities are miserably lax at reporting clinical trial results, analysis suggests

EU universities are miserably lax at reporting clinical trial results, analysis suggests

Endpoints

clinical trial data

clinical trials

Flag link:

Lynparza on cusp of EU approval for advanced ovarian cancer

Lynparza on cusp of EU approval for advanced ovarian cancer

Pharmaforum

Flag link:

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer

Pharmaforum

BRCA-mutant breast cancer

Flag link:

After falling short on prelim OS data, EMA tells Aveo it wants to see something better on its long suffering tivo this summer — or else

After falling short on prelim OS data, EMA tells Aveo it wants to see something better on its long suffering tivo this summer — or else

Endpoints

Flag link:

Teva wins EU nod for Ajovy migraine prophylactic

Teva wins EU nod for Ajovy migraine prophylactic

Drug Delivery Business News

Teva Pharmaceutical

Flag link:

AbbVie's massive Humira discounts are stifling Netherlands biosimilars: report

AbbVie's massive Humira discounts are stifling Netherlands biosimilars: report

Fierce Pharma

Flag link:

First gene therapy to treat rare blood disease nears European approval

First gene therapy to treat rare blood disease nears European approval

Stat

beta-thalassemia

Flag link:

Drug Sampling and Testing: EMA Releases 20 Year Report, Will Expand Program to Biosimilars

Drug Sampling and Testing: EMA Releases 20 Year Report, Will Expand Program to Biosimilars

RAPS.org

Flag link:

As Brexit row become increasingly anarchic, is UK’s reputation with pharma suffering?

As Brexit row become increasingly anarchic, is UK’s reputation with pharma suffering?

Pharmaforum

Flag link:

Pages